EGFR and non-small cell lung carcinoma: In 2022, the National Comprehensive Cancer Network (NCCN) expanded its guidelines for metastatic NSCLC to include “broad molecular profiles including EGFR (Figure 1A), ALK, HER2, MET, NTRK, RET, ROS1 (Figure 1B), KRAS, BRAF (Figure 1C), and PD-L1 (Figure 1D) [24].